Many of the challenges that delay scale-up, tech transfer, validation, clinical and commercial manufacturing can be traced back to decisions made during the earliest stages of development. As biologics become increasingly complex and development timelines continue to compress, designing with manufacturability in mind has become essential to achieving commercial success.
In this white paper, Justyna Adamczyk, Integrated Manufacturing Science &Technology (MS&T) Director at Rezon Bio, explores how biotech and biopharmaceutical companies can reduce development risk by integrating scalability, process robustness, and manufacturing readiness from the outset.
Download the white paper to learn:
- Why late-stage efficiency is a development strategy, not just a manufacturing objective
- How early process decisions influence technology transfer, validation timelines, and cost of goods (COGs)
- How platform-based development reduces complexity while enabling flexibility and faster execution
- Why risk-based validation approaches improve efficiency without compromising product quality or regulatory compliance
- How strategic development decisions can help accelerate path to commercialization
Access the full document to discover how to build manufacturability, scalability, and commercial readiness into your biologics program from day one.
